ABERRANT IMMUNE LANDSCAPE IN BONE MARROW OF HIGH-RISK MYELODYSPLASTIC SYNDROME PATIENTS

被引：0
|
作者：
Rai, R. [1 ]
Patel, F. [1 ]
Feld, J. [1 ]
Melana, S. [1 ]
Demakos, E. [1 ]
Horowitz, A. [2 ]
Silverman, L. [1 ]
机构：
[1] Tisch Canc Inst, Icahn Sch Med, Hematol Med Oncol, New York, NY USA
[2] Icahn Sch Med, Lipshultz Precis Immunol Inst, Tisch Canc Inst, Dept Oncol Sci, New York, NY USA
来源：
LEUKEMIA RESEARCH | 2023年 / 128卷
关键词：
D O I：
10.1016/j.leukres.2023.107215
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P080
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Decoding Bone Marrow Fibrosis in Myelodysplastic Syndrome
    Melody, Megan
    Al Ali, Najla H.
    Zhang, Ling
    Ramadan, Hanadi
    Padron, Eric
    Sallman, David
    Sweet, Kendra L.
    Lancet, Jeffrey E.
    List, Alan F.
    Bennett, John M.
    Komrokji, Rami S.
    BLOOD, 2016, 128 (22)
  • [42] Toll-like receptor and cytokine expression throughout the bone marrow differs between patients with low- and high-risk myelodysplastic syndromes
    Paracatu, Luana Chiquetto
    Monlish, Darlene A.
    Greenberg, Zev J.
    Fisher, Daniel A. C.
    Walter, Matthew J.
    Oh, Stephen T.
    Schuettpelz, Laura G.
    EXPERIMENTAL HEMATOLOGY, 2022, 110 : 47 - 59
  • [43] An Immune Risk Score Predicts Survival of Patients with Myelodysplastic Syndrome
    Liang, Yang
    Hu, Fang
    Dai, Yu-Jun
    Wang, Yun
    Li, Huan
    BLOOD, 2020, 136
  • [44] The unexplored immune landscape of high-risk pediatric cancers.
    Mayoh, Chelsea
    Terry, Rachael L.
    Wong, Marie
    Lau, Loretta M.
    Khuong-Quang, Dong Anh
    Mateos, Marion K.
    Tyrrell, Vanessa
    Haber, Michelle
    Ziegler, David S.
    Cowley, Mark J.
    Trapani, Joseph A.
    Neeson, Paul J.
    Ekert, Paul G.
    CANCER RESEARCH, 2021, 81 (13)
  • [45] Conditioning regimens for HSCT for patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukaemia
    Zhang, Xi
    LANCET HAEMATOLOGY, 2023, 10 (03): : e159 - e160
  • [46] Intensive treatment strategies in patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukemia
    Oosterveld, M
    de Witte, T
    BLOOD REVIEWS, 2000, 14 (04) : 182 - 189
  • [47] Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia
    Jain, Akriti G.
    Ball, Somedeb
    Aguirre, Luis
    Al Ali, Najla
    Kaldas, David
    Tinsley-Vance, Sara
    Kuykendall, Andrew
    Chan, Onyee
    Sweet, Kendra
    Lancet, Jeffrey E.
    Padron, Eric
    Sallman, David A.
    Komrokji, Rami
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 2157 - 2164
  • [48] Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia
    Jain, Akriti G.
    Ball, Somedeb
    Aguirre, Luis
    Al Ali, Najla
    Kaldas, David
    Tinsley-Vance, Sara
    Kuykendall, Andrew
    Chan, Onyee
    Sweet, Kendra
    Lancet, Jeffrey E.
    Padron, Eric
    Sallman, David A.
    Komrokji, Rami
    HAEMATOLOGICA, 2024, 109 (07) : 2157 - 2164
  • [49] Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
    Prebet, Thomas
    Gore, Steven D.
    Esterni, Benjamin
    Gardin, Claude
    Itzykson, Raphael
    Thepot, Sylvain
    Dreyfus, Francois
    Rauzy, Odile Beyne
    Recher, Christian
    Ades, Lionel
    Quesnel, Bruno
    Beach, C. L.
    Fenaux, Pierre
    Vey, Norbert
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) : 3322 - 3327
  • [50] Myelodysplastic Syndrome Azacitidine - useful therapeutic option in high-risk MDS
    Arnheim, Katharina
    ONKOLOGIE, 2010, 33 (12): : 720 - 721
12345